Chondrosarcoma Market Epidemiology, Growth Opportunities, and Pipeline Therapies and In-depth Analysis

Sarcomas are cancers that start in connective tissue, which are the body parts that have a supporting role in the body. The bones, cartilage, muscle, and blood are all types of connective tissue. Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis, and thigh bone. Chondrosarcoma can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by the syndrome. 

As with many cancers, the cause of Chondrosarcoma is not clear. However, Chondrosarcoma is associated with certain genetic mutations. Some varieties of Chondrosarcoma arise from the transformation of benign cartilage lesions into cancers. 

DelveInsight’s Chondrosarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Chondrosarcoma Market Report: 

  • According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcoma contributes to 30% of different types of bone cancer 

  • According to the American Cancer Society, Chondrosarcoma develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20 

  • According to the researchers, Chondrosarcoma is slightly more common in males than in females 

  • Bone tumors are rare diseases, and the Chondrosarcoma accounts for 25% to 40% of these tumors 

  • In 7 MM the total prevalence of Chondrosarcoma is estimated to be around 5,000 to 6,000 diagnosed cases each year 

Request a sample for the Report: https://www.delveinsight.com/sample-request/chondrosarcoma-market

Chondrosarcoma Symptoms: 

People with Chondrosarcoma usually do not feel sick. They may be able to feel a bony bump, and most patients ultimately will have pain, swelling, or limited movement that is caused by the tumor. The symptoms of Chondrosarcoma include-

  • Joint stiffness

  • Pain gets worse over the time

  • Weakness and limited joint movement

  • Large lump (mass) on a bone

  • The feeling of pressure around the lump

Chondrosarcoma Market 

The dynamics of the Chondrosarcoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as INBRX-109, AG-120, and others during the forecasted period 2019-2032. 

Learn more by requesting for sample @Chondrosarcoma Market Landscape  

Chondrosarcoma Pipeline Therapies:

  • INBRX-109

  • Pazopanib

  • AG-120

  • Trabectedin

  • PD-1 inhibitor 

Chondrosarcoma Pipeline Key Companies

  • Genentech

  • Infinity Pharmaceuticals

  • Agios Pharmaceuticals

  • IGM Biosciences

  • Forma Therapeutics

Click here to read more about Chondrosarcoma Market Outlook 2032

Latest Reports by DelveInsight

Comments

Popular posts from this blog

Innovations in Surgical Cameras and Their Impact on Healthcare

What is Chronic Wounds and why is its market booming?

Condom Market Report 2028: Market Size, Trends, and Forecast